News
1 October 2026
Fonko Strengthens Indonesia’s Oncology Industry Capacity
JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of "first copy" products for cancer therapy, and obtaining halal certification for its…
25 September 2026
Consistently Maintaining Halal Standards, Dexa Group Wins IHYA 2026
TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in…
24 September 2026
From Medications to Facilities, Ferron Strengthens Support for Cancer Patients
JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision…
27 June 2023
Commitment to Accelerate Stunting Reduction Prevalence to 14%, Dexa Medica and BKKBN Educate Thousand of Midwives
Various parties are involved in the pentahelix collaboration to pursue the stunting reduction target of 14% by 2024. To continue pursuinh the stunting reduction target set by President Joko Widodo, the National Population and Family Planning Agency (BKKBN) collaborated with Dexa Medica and the South Sumatra Provincial Government to hold…
1 June 2023
Contributing to Nation’s Health, Dexa Group Receives 2023 CSR Awards
Dexa Group's Dexa Award Science Scholarship program won an award in the healthcare and consumer category at the B-Universe CSR Awards. The award organized by B-Universe has the theme "Maximizing Shared Value Through Sustainable CSR Initiatives". The realization of this CSR Awards award was initiated from the message that President…
22 May 2023
Dexa Group, BKKBN, Polri, and IBI Collaborate to Achieve Target to Reduce Stunting Rate to 14% by 2024
The 2022 Indonesian Nutritional Status Survey (SSGI) shows that the national prevalence of stunting has decreased to by 2.8% to 21.6% compared to the previous year. Dexa Group collaborates with the National Population and Family Planning Board (BKKBN), the Indonesian National Police (Polri), and the Regional Government (Pemda) of Wonosobo…
21 May 2023
Caring for the Health of the Wonosobo Community, Dexa Group collaborates with the Local Government and the National Police to Hold Health Social Services
Dexa Group in collaboration with the Local Government (pemda) of Wonosobo Regency and the Indonesian National Police (Polri), held social services in the form of free health checks and medical treatment and the inauguration of communal latrines. This social service is intended to support and improve the health of the…
17 May 2023
Dexa Group Supports Health Resilience and Self-Sufficiency, Receiving Three Awards from the Ministry of Health
Dexa Group is committed to supporting government programs to increase the use of domestic pharmaceutical products to achieve health resilience and independence. For this reason, the Ministry of Health presented three awards to Dexa Group at the National Forum for Down Streaming and Increasing the Use of Domestic Pharmaceutical Products…
15 May 2023
STIMUNO Wins the 13th Consecutive Top Brand for Kids Award
STIMUNO, as the first phytopharmaca immunomodulator in Indonesia that has been clinically tested, maintains the end-to-end halal production process to provide comfort and safety for all Indonesian families. STIMUNO has also been declared safe by the Indonesian Food and Drug Authority (BPOM) through letter number B-PW.02.04.4.43.12.22.991. STIMUNO's positive progress, which…